Literature DB >> 29884911

RAC1-GTP promotes epithelial-mesenchymal transition and invasion of colorectal cancer by activation of STAT3.

Kai Zhou1,2, Jun Rao1,2,3, Zhi-Hua Zhou1,2, Xiao-Hong Yao1,2, Feng Wu1,2, Jing Yang1,2, Lang Yang1,4, Xia Zhang1,2, You-Hong Cui1,2, Xiu-Wu Bian5,6, Yu Shi7,8, Yi-Fang Ping9,10.   

Abstract

Epithelial-mesenchymal transition (EMT) plays a critical role in initiating tumor invasion and metastasis of colorectal cancer (CRC), although the underlying mechanisms remain to be clarified. Herein, we demonstrate that the active form of Rac family small GTPase 1 (RAC1-GTP) is overexpressed in CRCs and promotes the EMT-mediated invasion of CRC cells through activation of the signal transducers and activators of transcription 3 (STAT3) pathway. Increased expression of RAC1-GTP in CRC tissues was positively correlated with the TNM stages of CRCs and indicated poor prognosis of CRC patients. Targeting RAC1-GTP activity by its specific inhibitor NSC23766 markedly suppressed the migration and invasion of CRC cells. Mechanistically, RAC1-GTP directly interacted with STAT3 to promote STAT3 phosphorylation, thus promoted EMT of CRC cells. Enforced expression of constitutively activated STAT3 (STAT3-C) abrogated the suppressive effect of RAC1-GTP disruption on the migration and invasion of CRC cells. Importantly, NSC23766 disrupted EMT in CRC cells and significantly diminished growth of CRC xenografts. Taken together, our data indicate that RAC1-GTP is an important player in EMT-mediated tumor invasion and a potential therapeutic target for CRCs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29884911     DOI: 10.1038/s41374-018-0071-2

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  22 in total

Review 1.  Basics to advances in nanotherapy of colorectal cancer.

Authors:  Ankita Tiwari; Shivani Saraf; Ankit Jain; Pritish K Panda; Amit Verma; Sanjay K Jain
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

2.  T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1.

Authors:  Xiaoyu Ji; Xiaoping Chen; Bixiang Zhang; Meng Xie; Tongyue Zhang; Xiangyuan Luo; Danfei Liu; Yangyang Feng; Yijun Wang; Mengyu Sun; Congxin Li; Wenjie Huang; Limin Xia
Journal:  Oncogene       Date:  2022-02-26       Impact factor: 9.867

3.  Thwarting of Lphn3 Functions in Cell Motility and Signaling by Cancer-Related GAIN Domain Somatic Mutations.

Authors:  Monserrat Avila-Zozaya; Brenda Rodríguez-Hernández; Feliciano Monterrubio-Ledezma; Bulmaro Cisneros; Antony A Boucard
Journal:  Cells       Date:  2022-06-13       Impact factor: 7.666

4.  Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression.

Authors:  Yu-Lin Liu; Ze-Xuan Yan; Yu Xia; Xiao-Ye Xie; Kai Zhou; Li-Li Xu; Yan-Long Shi; Qiang Wang; Jing-Wang Bi
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

5.  Evaluation of active Rac1 levels in cancer cells: A case of misleading conclusions from immunofluorescence analysis.

Authors:  Martin J Baker; Mariana Cooke; Gabriel Kreider-Letterman; Rafael Garcia-Mata; Paul A Janmey; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2020-08-14       Impact factor: 5.157

Review 6.  Rho GTPases in cancer radiotherapy and metastasis.

Authors:  Rui-Jie Zeng; Chun-Wen Zheng; Wan-Xian Chen; Li-Yan Xu; En-Min Li
Journal:  Cancer Metastasis Rev       Date:  2020-08-08       Impact factor: 9.264

7.  MicroRNA‑142‑3p suppresses cell proliferation, invasion and epithelial‑to‑mesenchymal transition via RAC1‑ERK1/2 signaling in colorectal cancer.

Authors:  Na Xie; Qiuping Meng; Yixin Zhang; Zhifei Luo; Fenggui Xue; Sisi Liu; Ying Li; Yousheng Huang
Journal:  Mol Med Rep       Date:  2021-06-10       Impact factor: 2.952

Review 8.  Coordination between Rac1 and Rab Proteins: Functional Implications in Health and Disease.

Authors:  Azzurra Margiotta; Cecilia Bucci
Journal:  Cells       Date:  2019-04-29       Impact factor: 6.600

Review 9.  RAC1 Takes the Lead in Solid Tumors.

Authors:  Pradip De; Jennifer Carlson Aske; Nandini Dey
Journal:  Cells       Date:  2019-04-26       Impact factor: 6.600

Review 10.  Active RAC1 Promotes Tumorigenic Phenotypes and Therapy Resistance in Solid Tumors.

Authors:  Pradip De; Brett James Rozeboom; Jennifer Carlson Aske; Nandini Dey
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.